HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA To Consider Regulatory Shift Making Cannabis Ingredients Officially Eligible For Use In Dietary Supplements

Executive Summary

FDA's prohibition against using ingredients derived from the cannabis plant in supplements and food isn't lifted by the farm bill President Trump signed on Dec. 20, but the agency recognizes sales of supplement and food products containing cannabidiol and other cannabis derivatives are exploding in the US.

You may also be interested in...



After Aligning With FDA On Cannabinoids, California Lawmakers Move On Lawful Use

State Senate scheduled to vote on bill on 8 September and Assembly later in week. Floor votes prompted by amendment removing language that banned hemp smokables in the state, replaced by a phase-in approach.

Expanding Crop Of Ingredients Could Shrink Support For Lawful Use Of Hemp In Supplements

Groups of House and Senate members who opposed legislation to de-schedule hemp as a controlled substance in 2018 remain opposed to also legalizing cannabis and could stifle support for making lawful hemp’s use in supplements.

Absence Of Federal CBD Regulatory Pathway Complicates Doing Business In US, Clips Sales

“Irrational exuberance was an understatement for what people thought of the CBD market in 2018 and 2019,” says an attorney specializing in hemp regulations. In 2019, CBD isolate could be sold for “upwards of $12,000 a kilogram,” but price now is less than $1,000.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS148402

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel